JP Morgan Chase
XENE icon

JP Morgan Chase’s Xenon Pharmaceuticals XENE Stock Holding History

JP Morgan Chase’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-51,500
Closed -$1.76M – 7910
2023
Q3 		$1.76M Buy
+51,500
New +$1.93M ﹤0.01% 3637

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase's XENE Position: Q2 2026 in Review

JP Morgan Chase increased its Xenon Pharmaceuticals (XENE) stake by 36% in Q2 2026, buying an estimated $38.5M and bringing the position to 2,617,360 shares worth $157M. The position accounts for 0.01% of the portfolio, ranked #847.

JP Morgan Chase first reported a position in XENE in Q2 2016 and has held it in 36 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • JP Morgan Chase held 2,617,360 shares of Xenon Pharmaceuticals worth $157M as of Q2 2026.
  • JP Morgan Chase bought 693,750 Xenon Pharmaceuticals shares in Q2 2026, an estimated $38.5M.
  • Xenon Pharmaceuticals made up 0.01% of JP Morgan Chase's portfolio in Q2 2026, its #847 holding.
  • JP Morgan Chase first reported a position in Xenon Pharmaceuticals in Q2 2016 and has held it in 36 quarters since.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.